Edith Collins Centre (Translational Research in Alcohol, Drugs and Toxicology), Sydney Local Health District, Sydney, Australia.
Specialty of Addiction Medicine, Faculty of Medicine and Health, Central Clinical School (C39), The University of Sydney, Sydney, NSW, 2006, Australia.
Harm Reduct J. 2022 May 28;19(1):56. doi: 10.1186/s12954-022-00640-6.
Global commitment to achieving hepatitis C virus (HCV) elimination has enhanced efforts in improving access to direct-acting antiviral (DAA) treatments for people who inject drugs (PWID). Scale-up of efforts to engage hard-to-reach groups of PWID in HCV testing and treatment is crucial to success. Automatic needle/syringe dispensing machines (ADMs) have been used internationally to distribute sterile injecting equipment. ADMs are a unique harm reduction service, affording maximum anonymity to service users. This paper explores the feasibility and acceptability of extending the HCV cascade of care to sites where ADMs are located.
The ADM users into Treatment (ADMiT) study was undertaken in a metropolitan region in Sydney, Australia. This mixed methods study involved analysis of closed-circuit television footage, ethnographic methods (fieldwork observation and in-depth interviews) and structured surveys. Researchers and peers conducted fieldwork and data collection over 10 weeks at one ADM site, including offering access to HCV testing and treatment.
Findings from 10 weeks of fieldwork observations, 70 survey participants and 15 interviews highlighted that there is scope for engaging with this population at the time they use the ADM, and enhanced linkage to HCV testing and treatment may be warranted. Most survey participants reported prior HCV testing, 61% in the last 12 months and 38% had received HCV treatment. However, fieldwork revealed that most people observed using the ADM were not willing to engage with the researchers. Field work data and interviews suggested that extending the HCV cascade of care to ADMs may encroach on what is a private space for many PWID, utilized specifically to avoid engagement.
Enhanced linkage to HCV testing and treatment for people who use ADMs may be warranted. However, data suggested that extending the HCV cascade of care to ADMs may encroach on what is a private space for many PWID, utilized specifically to avoid engagement. The current study raises important public health questions about the need to ensure interventions reflect the needs of affected communities, including their right to remain anonymous.
全球致力于实现丙型肝炎病毒(HCV)消除,这增强了为注射毒品者(PWID)改善获得直接作用抗病毒(DAA)治疗的努力。扩大努力,使难以接触到的 PWID 群体接受 HCV 检测和治疗,对于取得成功至关重要。自动针/注射器分配机(ADM)已在国际上用于分发无菌注射设备。ADM 是一种独特的减少伤害服务,为服务使用者提供最大程度的匿名性。本文探讨了将 HCV 护理链扩展到 ADM 所在地点的可行性和可接受性。
ADM 用户进入治疗(ADMiT)研究在澳大利亚悉尼的一个大都市区进行。这项混合方法研究包括闭路电视录像分析、民族志方法(实地观察和深入访谈)和结构调查。研究人员和同行在一个 ADM 地点进行了 10 周的实地工作和数据收集,包括提供 HCV 检测和治疗。
在 10 周的实地观察、70 名调查参与者和 15 次访谈中发现,在 PWID 使用 ADM 的同时,与该人群接触是有空间的,并且可能需要加强 HCV 检测和治疗的联系。大多数调查参与者报告了过去的 HCV 检测,61%在过去 12 个月内,38%接受了 HCV 治疗。然而,实地工作发现,大多数观察到使用 ADM 的人不愿意与研究人员接触。实地工作数据和访谈表明,将 HCV 护理链扩展到 ADM 可能会侵犯许多 PWID 的私人空间,他们特别利用这个空间来避免接触。
为使用 ADM 的人增强 HCV 检测和治疗的联系可能是必要的。然而,数据表明,将 HCV 护理链扩展到 ADM 可能会侵犯许多 PWID 的私人空间,他们特别利用这个空间来避免接触。本研究提出了关于干预措施是否需要反映受影响社区需求的重要公共卫生问题,包括他们保持匿名的权利。